Revolution Medicines, Inc.
NASDAQRevolution Medicines is trading at $190.46 — up 28% over the past month and now within touching distance of the Street's mean price target — creating a fresh question about whether the re-rating has run its course or still has legs. The most notable Street development this week is Mizuho raising its target to $215 from $185 on July 6, while keeping an Outperform rating. That move…
RVMD put-call ratio crashes to 0.39, hitting 4.2 standard deviations below the 20-day mean of 0.98—extreme bullish signal as traders dump puts.
Snapshot as of 6 Aug 2026
Revolution Medicines is trading at $190.46 — up 28% over the past month and now within touching distance of the Street's mean price target — creating a fresh question about whether the re-rating has run its course or…
Revolution Medicines enters July with an unusually clear alignment between analyst conviction and options sentiment — both shifting decisively in the bulls' favour even as insiders quietly lock in gains. The most…
Revolution Medicines heads into its June 18 Q1 results with the Street's conviction rising and short sellers quietly rebuilding positions after a month of covering. The analyst story is the dominant theme this week.…
Revolution Medicines reports Q1 2026 results today having become one of the most striking momentum stories in biotech this year. The stock closed at $151.07, up 52% over the past month and 7.5% on the week alone — a…
Revolution Medicines heads into its Q1 2026 earnings release with a rare alignment: a landmark clinical publication, a collapsing short position, and a Wall Street analyst community that has spent two weeks racing to…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for RVMD — free to start on ORTEX.
Sign up for free →Open RVMD on ORTEX